ORIGINAL RESEARCH
Published on 20 May 2022
Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma
doi 10.3389/fimmu.2022.879983
- 4,496 views
- 9 citations
- Frontiers in Oncology
- Cancer Genetics
- Research Topics
- Adoptive T-Cell Therapy, iPSCs Technology, and the CRISPR/Cas9 Genome Editing System: A New Frontier in Cancer Treatment
Adoptive T-Cell Therapy, iPSCs Technology, and the CRISPR/Cas9 Genome Editing System: A New Frontier in Cancer Treatment
17k
Total downloads
57k
Total views and downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Articles
REVIEW
Published on 01 Mar 2022
Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy
doi 10.3389/fimmu.2022.848327
- 10,186 views
- 27 citations
ORIGINAL RESEARCH
Published on 16 Feb 2022
Repolarization of Tumor-Infiltrating Myeloid Cells for Augmentation of CAR T Cell Therapies
doi 10.3389/fimmu.2022.816761
- 4,075 views
- 20 citations
ORIGINAL RESEARCH
Published on 18 Jan 2022
Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains
doi 10.3389/fonc.2021.802876
- 13,829 views
- 16 citations
ORIGINAL RESEARCH
Published on 10 Jan 2022
Evaluation of Nonviral piggyBac and lentiviral Vector in Functions of CD19chimeric Antigen Receptor T Cells and Their Antitumor Activity for CD19+ Tumor Cells
doi 10.3389/fimmu.2021.802705
- 5,945 views
- 9 citations
ORIGINAL RESEARCH
Published on 04 Jan 2022
High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study
doi 10.3389/fimmu.2021.779248
- 3,054 views
- 8 citations
ORIGINAL RESEARCH
Published on 03 Jan 2022
Co-Expression of miR155 or LSD1 shRNA Increases the Anti-Tumor Functions of CD19 CAR-T Cells
doi 10.3389/fimmu.2021.811364
- 5,142 views
- 19 citations
ORIGINAL RESEARCH
Published on 17 Nov 2021
Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells
doi 10.3389/fimmu.2021.782448
- 3,536 views
- 21 citations
Published in
Frontiers in Oncology
- Cancer Genetics
- Cancer Immunity and Immunotherapy
Participating Journals
Frontiers in Immunology
- 5.7 impact factor
- 9.8 citescore
Impact
- 57kTopic views
- 39kArticle views
- 17kArticle downloads